logo color s and clearside.jpg
Clearside Biomedical Suprachoroidal Delivery Technology to be Featured at Upcoming ASRS and OIS Medical Meetings
July 07, 2022 07:05 ET | Clearside Biomedical, Inc.
- Multiple Podium and Poster Presentations on XIPERE® and Gene Therapy Delivery Utilizing SCS Microinjector® - ALPHARETTA, Ga., July 07, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq:...
logo color s and clearside.jpg
Clearside Biomedical’s Suprachoroidal Injection Platform Featured at the Angiogenesis, Exudation, and Degeneration 2022 Virtual Conference
February 14, 2022 16:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the...
logo color s and clearside.jpg
Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
September 21, 2021 07:05 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Sept. 21, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
logo color s and clearside.jpg
Clearside Biomedical, Inc. to Present at the Cowen and Company 37th Annual Health Care Conference
March 01, 2017 17:00 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 01, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Receives Notice of Allowance for Ninth U.S. Patent
March 01, 2017 08:00 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., March 01, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Redirects Pre-Clinical AMD Research Resources Toward Ongoing DME Clinical Development Program
February 27, 2017 08:00 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Announces First Patient Randomized in Phase 3 Clinical Trial of Zuprata™ Used Together With Eylea in Subjects With Retinal Vein Occlusion
February 16, 2017 07:30 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Feb. 16, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Receives Notice of Allowance for Seventh U.S. Patent
January 05, 2017 16:30 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 05, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Appoints Richard Beckman, M.D., as Chief Medical Officer
January 04, 2017 16:30 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Jan. 04, 2017 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye...
logo color s and clearside.jpg
Clearside Biomedical, Inc. Added to NASDAQ Biotechnology Index
December 14, 2016 16:15 ET | Clearside Biomedical, Inc.
ALPHARETTA, Ga., Dec. 14, 2016 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat...